Observational studyJournal of managed care & specialty pharmacy2021

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.

Justin S Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.